Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00889889 | Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination | PHASE2 | COMPLETED | 1,270 | — | — | May 1, 2009 | Jan 1, 2011 | Oct 25, 2013 | 15 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cell-Derived Trivalent Subunit Influenza Vaccine | BIOLOGICAL | surface antigen, inactivated, prepared in cell cultures |
| Placebo | BIOLOGICAL | Placebo |
Inclusion Criteria 1. Willing and able to give informed consent and able to adhere to all protocol required study procedures. 2. Men and women aged \>= 18 and \<= 64 years. 3. Being in good health as judged by medical history, physical examination and clinical judgment of the investigator. Exclusi...